Testing whether repeat surgery can be avoided after bladder tumor removal
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial looks at whether people with early bladder cancer can safely skip a second surgery after their first procedure fully removed the tumor with clear margins. It may help avoid extra procedures and associated discomfort, if your cancer meets the study’s “low-risk” criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had an endoscopic bladder tumor removal (ERBT) and your pathology showed pT1 cancer.
- Your first pathology report showed clear margins in both directions (no cancer at the vertical and horizontal edges).
- Your tumor size/location must be suitable for ERBT (not considered too large for this approach).
- There should be no leftover tumor seen after the first surgery.
- You should not have too many separate tumor spots (4 or fewer lesions only).
- You should not have CIS (carcinoma in situ, a flat high-risk abnormal area in the bladder).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares the need for a second surgery for people with early-stage bladder cancer. It uses a simple urine test to see if the test can help decide whether a second operation is necessary, which could save some patients from an extra procedure.
This trial tests STM-416, given around the time you have surgery to remove recurring bladder tumors, to see if it can reduce the chance the cancer comes back. It is for people with high-risk early bladder cancer (non–muscle-invasive) who have already had standard treatment and now need another TURBT.
This study looks at whether a second bladder surgery is still needed for people with high-risk bladder cancer who had a negative urine test after their first surgery.
This trial checks whether a bladder scan and score (VI-RADS from MRI) can help doctors choose the right way to do a second look surgery for non-muscle-invasive bladder cancer. The goal is to reduce the chance of needing extra (“secondary”) resections while still catching important disease early.
This study looks at whether removing nearby lymph nodes during radical cystectomy (bladder removal) improves outcomes for people with high-risk non–muscle-invasive bladder cancer. It may help doctors choose the best surgical approach to reduce the chance of cancer coming back.
This trial is testing whether a urine test for tumor DNA/RNA can help guide the decision for a second surgery in people with high-risk, non-muscle-invasive bladder cancer. It aims to see if the urine test can predict who needs the second surgery, potentially avoiding unnecessary procedures.
Hear when a new Bladder Cancer Stage I trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.